Evidence map›Paper›PMID 22038353›Full record

ArticleJournal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban2011

Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?

Shuang Wei, Xiaoyi Hao, Daqian Zhan, Min Xiong, Kaiyan Li, Xiaoping Chen, Zhiyong Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2016
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuang WeiResearch Laboratory and Hepatic Surgical Center, Department of Surgery, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xiaoyi HaoResearch Laboratory and Hepatic Surgical Center, Department of Surgery, Huazhong University of Science and Technology, Wuhan, 430030, China.
Daqian ZhanResearch Laboratory and Hepatic Surgical Center, Department of Surgery, Huazhong University of Science and Technology, Wuhan, 430030, China.
Min XiongDepartment of Obstetrics and Gynecology, Huazhong University of Science and Technology, Wuhan, 430030, China.
Kaiyan LiDepartment of Ultrasonic Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Xiaoping ChenResearch Laboratory and Hepatic Surgical Center, Department of Surgery, Huazhong University of Science and Technology, Wuhan, 430030, China. chenxp@medmail.com.cn.
Zhiyong HuangResearch Laboratory and Hepatic Surgical Center, Department of Surgery, Huazhong University of Science and Technology, Wuhan, 430030, China. zyhuang@medmail.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver resection is the most effective treatment for hepatocellular carcinoma (HCC). The Barcelona Clinic Liver Cancer (BCLC) staging system is commonly accepted as a guideline for HCC treatment, but it only recommends liver resection for the patients with HCC at stage 0 to A1. The surgical indications of the BCLC staging system need to be re-evaluated. 120 HCC patients undergoing curative liver resection were retrospectively stratified to the BCLC staging system, and the survival of the patients at stages A, B and C was analyzed. The justification of the BCLC staging system was re-evaluated. Fifty-two patients were classified at stage A, 51 at stage B and 17 at stage C respectively. The hospital mortality of this cohort was zero and the morbidity was 24.1%. The 1-, 2-, 3-year overall survival rate of this cohort was 81.6%, 68.3%, and 57.5% respectively. There was no significant difference in the survival rate between the patients at stage A and B (P>0.05). If the treatment guidelines of BCLC staging system were followed, the majority of the patients at stages A and B (77.7%, 80/103) would not have been treated surgically. Our data suggest that the surgical indications of the BCLC staging system are not justified for HCC treatment. More studies may be needed as for how to further broaden the surgical indications of the BCLC staging system in the future.

Indexed as

AdultCarcinoma, HepatocellularCohort StudiesFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPatient SelectionPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID22038353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.